Results 31 to 40 of about 105,726 (291)
Pharmaceutics, 2021 Tacrolimus presents high intra and inter-individual variability in its blood trough concentration (Cmin). Knowledge of the factors that are involved in tacrolimus Cmin variability is thus clinically important to prevent or limit it.
Anaelle Chavant +5 more
doaj +1 more source
Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis. [PDF]
PLoS ONE, 2015 BACKGROUND AND OBJECTIVE:The association between the CYP3A4*1B single nucleotide polymorphism (SNP) and tacrolimus pharmacokinetics in different studies is controversial.
Wei-Long Shi, Hui-Lin Tang, Suo-Di Zhai
doaj +1 more source
A case report: acute pancreatitis associated with tacrolimus in kidney transplantation
BMC Nephrology, 2019 Background Tacrolimus has been widely used for immunosuppressive therapy in solid organ transplantation (SOT) and allo-geneic stem cell transplantation (allo-SCT) over the past 2 decades.
Junnan Xu +4 more
doaj +1 more source
Evidence of a clinically significant drug‐drug interaction between cannabidiol and tacrolimus
American Journal of Transplantation, 2019 Cannabidiol (CBD), a major purified nonpsychoactive component of cannabis with anticonvulsant properties, was approved by the U.S. Food and Drug Administration (FDA) in June 2018 as an adjuvant treatment for refractory epilepsy (Epidiolex; GW ...
A. Leino +5 more
semanticscholar +1 more source
The Annals of Pharmacotherapy, 2020 Background: Medication nonadherence is a leading cause of late allograft loss in kidney transplantation (KT). Tacrolimus trough coefficient of variation (CV), measured using the coefficient of variation, is strongly correlated with acute rejection, graft
J. McGillicuddy +3 more
semanticscholar +1 more source
Cell Transplantation, 2012 Basiliximab is a recently developed immunosuppressive agent for the prevention of acute allograft rejection in renal transplant recipients. The combination use of basiliximab and a calcineurin inhibitor was suggested to be more effective in comparison to
Kentaro Sugiyama Ph.D. +9 more
doaj +1 more source
Clinical pharmacology and therapy, 2015 Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose‐adjusted trough concentrations of
K. Birdwell +15 more
semanticscholar +1 more source
Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation
Current drug metabolism, 2018 Background: Tacrolimus (Tac, or FK506), a calcineurin inhibitor (CNI), is the first-line immu-nosuppressant which consists of the footstone as immunosuppressive regimens in kidney transplantation.
Meng Yu, Mou-Ze Liu, Wei Zhang, Y. Ming
semanticscholar +1 more source
Pharmacokinetics of Tacrolimus in Egyptian Liver Transplant Recipients: Role of the Classic Co-variables [PDF]
Journal of Advanced Pharmacy Research, 2019 Objectives: This work was performed to study the pharmacokinetics of tacrolimus in adult liver transplant recipients after optimization of all the known classic factors contributing to inter-patient variability in whole blood tacrolimus levels.
Abdel-hamid Ebid +3 more
doaj +1 more source